TABLE OF CONTENTS
Clinician Patient Referral Guide
Clinician Referral Form
Institutional Partnership Introduction
How to Refer
FAQ
Appendices
CANCER HUNT INITIATIVE
TargeTx Study Summary
TARGETx — Tumor Analysis of Rates of Genomic Evidence for Targeted Treatment
STUDY OVERVIEW
Study type
Minimal-risk biospecimen, genomic profiling, navigation, and research study. IRB-supported. Not a treatment trial — TargeTx does not direct therapy, replace the treating oncologist, or require changes in standard-of-care.
Sponsors
SOTERIA Precision Medicine Foundation in conjunction with TGen (City of Hope) for research-use-only WGS analysis and multidisciplinary Molecular Tumor Board review.
Population
U.S. military veterans with active cancer diagnoses. Typically stage IIIB–IV. Earlier stage considered at investigator discretion.
ELIGIBILITY OVERVIEW
Participants are generally eligible if they meet all of the following:
Age 18 or older
Active cancer diagnosis — primarily solid tumors; brain and blood cancers evaluated individually
Stage IIIB–IV preferred; earlier stage considered at investigator discretion
Accessible medical records
Available tumor tissue or cells from prior or upcoming standard-of-care biopsy or resection — no research-only biopsy required
Willing to donate residual biospecimens
Willing to engage with SOTERIA nurse navigation
Note: Protocol allows investigator discretion for earlier-stage cancers and selected Intelligence Community field-agent cases.
Research-use only (RUO — TGen)
Mutational signature analysis
Copy-number analysis
RNA / transcriptome analysis
Comparison with public datasets
RUO findings are not returned directly to participants and require clinical validation before clinical use. CLIA-validated reports are returned to SOTERIA, the participant, and the treating physician.
PROTOCOL FLOW
Identification & intake: SOTERIA consents eligible participants, consolidates medical records
Tissue coordination: FFPE, fresh frozen, saliva, buccal swab, or blood; from prior or clinically indicated procedures only
Sequencing: CLIA-certified labs for clinical testing; TGen for RUO analysis
Molecular Tumor Board: convened for select cases; treating physicians invited
Results delivery: CLIA reports returned to patient and treating team; plain-language summary prepared by SOTERIA
Longitudinal follow-up: outcomes tracking, treatment response, exposureomics analysis
KEY OBJECTIVES
Primary: Measure the frequency of potentially treatment-relevant genomic targets identified in tumors from U.S. military personnel.
Secondary: Sample procurement time, testing turnaround, time to return of results, cancer types represented, patient satisfaction with navigation.
Exploratory: Identify molecular signatures, compare findings with non-military datasets, collect outcomes data, and characterize exposure-linked patterns.
TESTING & SEQUENCING
Clinical testing (CLIA-certified)
Whole Exome Sequencing (WES) — tumor/normal
Whole Transcriptome Sequencing (WTS)
Whole Genome Sequencing for selected indications
Germline panel (BRCA1/2, ATM, CDK12, and others)
CLINICAL & REFERRAL INQUIRIES
VETERAN COMMUNITY OUTREACH
You Don’t Have To Navigate This Journey Alone
Schedule a Consult
If you are navigating a cancer diagnosis, don’t fight alone.
Our dedicated team is ready to help you access the personalized, genomic-led care you deserve. Take the first step today by scheduling with one of our navigators.
Donate to the Mission
Every dollar makes a difference for our Special Operations Community.
Your gift provides immediate and lifesaving access to genomic testing and expert navigation.